European Journal of Medical and Health Research, Год журнала: 2025, Номер 3(2), С. 122 - 135

Опубликована: Март 23, 2025

Obesity is a known risk factor for various cancers, influencing carcinogenesis through metabolic, hormonal, and inflammatory pathways. Excess adiposity leads to insulin resistance, chronic inflammation, hormonal imbalances, all of which contribute tumor development. increases the cancers in endocrine system (e.g., thyroid, pancreatic, adrenal) due resistance altered hormone levels. In reproductive system, it raises breast, ovarian, endometrial, prostate dysregulation inflammation. also linked digestive including esophageal, liver, colorectal metabolic dysfunction The role obesity lung cancer remains debated, but changes may influence progression. contributes hematologic such as leukemia, by altering immune function promoting Other systems show varying associations with risk. Key mechanisms include dysregulation, epigenetic changes, elevated insulin/IGF-1, promote growth. Early detection imaging biomarkers, along lifestyle diet, exercise) pharmacologic treatments metformin, GLP-1 agonists), can reduce improve outcomes. Personalized treatment obese patients requires adjustments surgery, chemotherapy, radiotherapy, immunotherapy. This review explores obesity’s association across body systems, overviews contributing carcinogenesis, summarizes clinical public health implications, screening, prevention, treatment, policy interventions.

Язык: Английский